Significant biological role of Sp1 transactivation in multiple myeloma

Clinical Cancer Research

Volumn 17, Issue 20, 2011, Pages 6500-6509

  Fulciniti, Mariateresa ^a,b   Amin, Samir ^a   Nanjappa, Puru ^a   Rodig, Scott ^a   Prabhala, Rao ^b   Li, Cheng ^a   Minvielle, Stephane ^c   Tai, Yu Tzu ^a   Tassone, Pierfrancesco ^d   Avet Loiseau, Herve ^c   Hideshima, Teru ^a   Anderson, Kenneth C ^a   Munshi, Nikhil C ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c NANTES UNIVERSITY HOSPITAL   (France)

^d UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 9; FIREFLY LUCIFERASE; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TERAMEPROCOL; TRANSCRIPTION FACTOR SP1;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN FUNCTION; REPORTER GENE; STROMA CELL;

ANIMALS; APOPTOSIS; BONE MARROW CELLS; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; GENE KNOCKDOWN TECHNIQUES; HUMANS; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, SCID; MULTIPLE MYELOMA; NORDIHYDROGUAIARETIC ACID; RNA INTERFERENCE; SP1 TRANSCRIPTION FACTOR; TRANSCRIPTIONAL ACTIVATION; TUMOR CELLS, CULTURED;

EID: 80054115013     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1036     Document Type: Article

References (50)

1. Suske G. The Sp-family of transcription factors. Gene 1999;238:291-300. (Pubitemid 29446168)
2. Naar AM, Ryu S, Tjian R. Cofactor requirements for transcriptional activation by Sp1. Cold Spring Harb Symp Quant Biol 1998;63:189-99. (Pubitemid 29282163)
3. Suzuki T, Kimura A, Nagai R, Horikoshi M. Regulation of interaction of the acetyltransferase region of p300 and the DNA-binding domain of Sp1 on and through DNA binding. Genes Cells 2000;5:29-41. (Pubitemid 30095679)
4. Zhao S, Venkatasubbarao K, Li S, Freeman JW. Requirement of a specific Sp1 site for histone deacetylase-mediated repression of transforming growth factor beta type II receptor expression in human pancreatic cancer cells. Cancer Res 2003;63:2624-30. (Pubitemid 36605205)
5. Black AR, Black JD, Azizkhan-Clifford J. Sp1 and Kruppel-like factor family of transcription factors in cell growth regulation and cancer. J Cell Physiol 2001;188:143-60. (Pubitemid 32622905)
6. Abdelrahim M, Samudio I, Smith R III, Burghardt R, Safe S. Small inhibitory RNA duplexes for Sp1 mRNA block basal and estrogeninduced gene expression and cell cycle progression in MCF-7 breast cancer cells. J Biol Chem 2002;277:28815-22.
7. Abdelrahim M, Safe S. Cyclooxygenase-2 inhibitors decrease vascular endothelial growth factor expression in colon cancer cells by enhanced degradation of Sp1 and Sp4 proteins. Mol Pharmacol 2005;68:317-29. (Pubitemid 41058295)
8. Kanai M, Wei D, Li Q, Jia Z, Ajani J, Le X, et al. Loss of Kruppel-like factor 4 expression contributes to Sp1 overexpression and human gastric cancer development and progression. Clin Cancer Res 2006; 12:6395-402. (Pubitemid 44799710)
9. Shi Q, Le X, Abbruzzese JL, Peng Z, Qian CN, Tang H, et al. Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res 2001;61:4143-54. (Pubitemid 32720983)
10. Abdelrahim M, Baker CH, Abbruzzese JL, Sheikh-Hamad D, Liu S, Cho SD, et al. Regulation of vascular endothelial growth factor receptor-1 expression by specificity proteins 1, 3, and 4 in pancreatic cancer cells. Cancer Res 2007;67:3286-94. (Pubitemid 46724867)
11. Jungert K, Buck A, von Wichert G, Adler G, Konig A, Buchholz M, et al. Sp1 is required for transforming growth factor-beta-induced mesenchymal transition and migration in pancreatic cancer cells. Cancer Res 2007;67:1563-70. (Pubitemid 46383380)
12. Jiang NY, Woda BA, Banner BF, Whalen GF, Dresser KA, Lu D. Sp1, a new biomarker that identifies a subset of aggressive pancreaticductal adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2008;17: 1648-52.
13. Chiefari E, Brunetti A, Arturi F, Bidart JM, Russo D, Schlumberger M, et al. Increased expression of AP2 and Sp1 transcription factors in human thyroid tumors: a role in NIS expression regulation? BMC Cancer 2002;2:35.
14. Wang L, Wei D, Huang S, Peng Z, Le X, Wu TT, et al. Transcription factor Sp1 expression is a significant predictor of survival in human gastric cancer. Clin Cancer Res 2003;9:6371-80. (Pubitemid 38031822)
15. Yuan P, Wang L, Wei D, Zhang J, Jia Z, Li Q, et al. Therapeutic inhibition of Sp1 expression in growing tumors by mithramycin a correlates directly with potent antiangiogenic effects on human pancreatic cancer. Cancer 2007;110:2682-90. (Pubitemid 350250337)
16. Ishibashi H, Nakagawa K, Onimaru M, Castellanous EJ, Kaneda Y, Nakashima Y, et al. Sp1 decoy transfected to carcinoma cells suppresses the expression of vascular endothelial growth factor, transforming growth factor beta1, and tissue factor and also cell growth and invasion activities. Cancer Res 2000;60:6531-6.
17. Lou Z, O'Reilly S, Liang H, Maher VM, Sleight SD, McCormick JJ. Down-regulation of overexpressed sp1 protein in human fibrosarcoma cell lines inhibits tumor formation. Cancer Res 2005;65: 1007-17. (Pubitemid 40216463)
18. Abdelrahim M, Liu S, Safe S. Induction of endoplasmic reticuluminduced stress genes in Panc-1 pancreatic cancer cells is dependent on Sp proteins. J Biol Chem 2005;280:16508-13. (Pubitemid 40616782)
19. Chuang JY, Wang YT, Yeh SH, Liu YW, Chang WC, Hung JJ. Phosphorylation by c-Jun NH2-terminal kinase 1 regulates the stability of transcription factor Sp1 during mitosis. Mol Biol Cell 2008;19: 1139-51.
20. Verrecchia F, Rossert J, Mauviel A. Blocking sp1 transcription factor broadly inhibits extracellular matrix gene expression in vitro and in vivo: implications for the treatment of tissue fibrosis. J Invest Dermatol 2001;116:755-63. (Pubitemid 32467656)
21. Benasciutti E, Pages G, Kenzior O, Folk W, Blasi F, Crippa MP. MAPK and JNK transduction pathways can phosphorylate Sp1 to activate the uPA minimal promoter element and endogenous gene transcription. Blood 2004;104:256-62. (Pubitemid 38879866)
22. Sroka IC, Nagle RB, Bowden GT. Membrane-type 1 matrix metalloproteinase is regulated by sp1 through the differential activation of AKT, JNK, and ERK pathways in human prostate tumor cells. Neoplasia 2007;9:406-17. (Pubitemid 46799984)
23. Tan NY, Khachigian LM. Sp1 phosphorylation and its regulation of gene transcription. Mol Cell Biol 2009;29:2483-8.
24. Chu S, Ferro TJ. Sp1: regulation of gene expression by phosphorylation. Gene 2005;348:1-11. (Pubitemid 40410011)
25. Gerlo S, Haegeman G, Vanden Berghe W. Transcriptional regulation of autocrine IL-6 expression in MM cells. Cell Signal 2008;20:1489-96.
26. Cooke DW, Bankert LA, Roberts CT Jr, LeRoith D, Casella SJ. Analysis of the human type I insulin-like growth factor receptor promoter region. Biochem Biophys Res Commun 1991;177:1113-20.
27. Takakura M, Kyo S, Kanaya T, Hirano H, Takeda J, Yutsudo M, et al. Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res 1999;59:551-7. (Pubitemid 29076049)
28. Ueberla K, Lu Y, Chung E, Haseltine WA. The NF-kappa B p65 promoter. J Acquir Immune Defic Syndr 1993;6:227-30.
29. Fulciniti M, Tassone P, Hideshima T, Vallet S, Nanjappa P, Ettenberg SA, et al. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for MM. Blood 2009;114:371-9.
30. Lopez RA, Goodman AB, Rhodes M, Blomberg JA, Heller J. The anticancer activity of the transcription inhibitor terameprocol (mesotetra- O-methyl nordihydroguaiaretic acid) formulated for systemic administration. Anticancer Drugs 2007;18:933-9. (Pubitemid 47220712)
31. Hideshima T, Mitsiades C, Ikeda H, Chauhan D, Raje N, Gorgun G, et al. A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in MM cells. Blood 2010;115: 3772-5.
32. Tai YT, Fulciniti M, Hideshima T, Song W, Leiba M, Li XF, et al. Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. Blood 2007;110:1656-63. (Pubitemid 47443984)
33. Hwu JR, Tseng WN, Gnabre J, Giza P, Huang RC. Antiviral activities of methylated nordihydroguaiaretic acids. 1. Synthesis, structure identification, and inhibition of tat-regulated HIV transactivation. J Med Chem 1998;41:2994-3000. (Pubitemid 28359934)
34. Chen H, Teng L, Li JN, Park R, Mold DE, Gnabre J, et al. Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA. J Med Chem 1998;41: 3001-7. (Pubitemid 28359935)
35. Gnabre JN, Brady JN, Clanton DJ, Ito Y, Dittmer J, Bates RB, et al. Inhibition of human immunodeficiency virus type 1 transcription and replication by DNA sequence-selective plant lignans. Proc Natl Acad Sci U S A 1995;92:11239-43.
36. Dohm JA, Hsu MH, Hwu JR, Huang RC, Moudrianakis EN, Lattman EE, et al. Influence of ions, hydration, and the transcriptional inhibitor P4N on the conformations of the Sp1 binding site. J Mol Biol 2005; 349:731-44. (Pubitemid 40725951)
37. Li F, Altieri DC. The cancer antiapoptosis mouse survivin gene: characterization of locus and transcriptional requirements of basal and cell cycle-dependent expression. Cancer Res 1999;59: 3143-51. (Pubitemid 29316014)
38. Smolewski P. Terameprocol, a novel site-specific transcription inhibitor with anticancer activity. IDrugs 2008;11:204-14. (Pubitemid 351323375)
39. Chun JY, Hu Y, Pinder E, Wu J, Li F, Gao AC. Selenium inhibition of survivin expression by preventing Sp1 binding to its promoter. Mol Cancer Ther 2007;6:2572-80. (Pubitemid 47480423)
40. Mityaev MV, Kopantzev EP, Buzdin AA, Vinogradova TV, Sverdlov ED. Functional significance of a putative sp1 transcription factor binding site in the survivin gene promoter. Biochemistry 2008;73: 1183-91.
41. Xu R, Zhang P, Huang J, Ge S, Lu J, Qian G. Sp1 and Sp3 regulate basal transcription of the survivin gene. Biochem Biophys Res Commun 2007;356:286-92. (Pubitemid 46413162)
42. Li Y, Xie M, Yang J, Yang D, Deng R, Wan Y, et al. The expression of antiapoptotic protein survivin is transcriptionally upregulated by DEC1 primarily through multiple sp1 binding sites in the proximal promoter. Oncogene 2006;25:3296-306. (Pubitemid 43846314)
43. Konduri S, Colon J, Baker CH, Safe S, Abbruzzese JL, Abudayyeh A, et al. Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by inhibiting survivin protein expression. Mol Cancer Ther 2009;8:533-42.
44. Abdelrahim M, Baker CH, Abbruzzese JL, Safe S. Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation. J Natl Cancer Inst 2006;98:855-68. (Pubitemid 43923442)
45. Doetzlhofer A, Rotheneder H, Lagger G, Koranda M, Kurtev V, Brosch G, et al. Histone deacetylase 1 can repress transcription by binding to Sp1. Mol Cell Biol 1999;19:5504-11. (Pubitemid 29339908)
46. Xu J, Zhou JY, Wei WZ, Philipsen S, Wu GS. Sp1-mediated TRAIL induction in chemosensitization. Cancer Res 2008;68:6718-26.
47. Liu S, Liu Z, Xie Z, Pang J, Yu J, Lehmann E, et al. Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia. Blood 2008;111:2364-73. (Pubitemid 351451445)
48. Goffin L, Seguin-Estevez Q, Alvarez M, Reith W, Chizzolini C. Transcriptional regulation of matrix metalloproteinase-1 and collagen 1A2 explains the anti-fibrotic effect exerted by proteasome inhibition in human dermal fibroblasts. Arthritis Res Ther 2010;12:R73.
49. Kikuchi J, Wada T, Shimizu R, Izumi T, Akutsu M, Mitsunaga K, et al. Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in MM. Blood 2010;116;406-17.
50. Escoubet-Lozach L, Lin IL, Jensen-Pergakes K, Brady HA, Gandhi AK, Schafer PH, et al. Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and MM through a LSD1- mediated epigenetic mechanism. Cancer Res 2009;69:7347-56.